Антипсихотические препараты: тактика назначения и смены на разных этапах терапии


Д.В. Ястребов

ФГУ “Государственный научный центр социальной и судебной психиатрии им. В.П. Сербского” Минздравсоцразвития России, Москва
В обзорной статье рассмотрены основные аспекты антипсихотической терапии с использованием атипичных антипсихотических препаратов, обсуждаются вопросы тактики ее назначения и этапного ведения пациентов. Представлены алгоритмы антипсихотической терапии при шизофренических психозах и биполярного расстройства.

Литература


1. Авруцкий Г.Я., Недува А.А. Лечение психически больных. М., 1988. 528 с.
2. Мосолов С.Н. Основы психофармакотерапии. М., 1996. 288 с.
3. Arana G, Rosenbaum J. Handbook of Psychiatric Drug Therapy, 4th ed. 2001:255.
4. Baghdady NT, Banik S, Swartz SA, et al. Psychotropic drugs and renal failure: translating the evidence for clinical practice. Adv Ther 2009;26:404–24.
5. Beasley CM, Sanger T, Satterlee W, et al. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996;124:159–67.
6. Bergemann N, Frick A, Parzer P, et al. Olanzapine plasma concentration, average daily dose, and
interaction with comedication in schizophrenic patients. Pharmacopsyсhiatry 2004;37:63–8.
7. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine. Pharmacokinetic and pharmacodynamic
profile. Clin Pharmacokinet 1999;37:177–93.
8. Chiesa A, Chierzi F, De Ronchi D, Serretti A. Quetiapine for bipolar depression: a systematic review and meta-analysis. Int Clin Psychopharmacol 2012;27(2):76–90.
9. Cohen LG, Fatalo A, Thompson BT, et al. Olanzapine overdose with serum concentrations. Ann Emerg Med 1999;34:275–78.
10. Essock SM, Covell NH, Davis SM, et al. Effectiveness of switching antipsychotic medications. Am J Psychiatry 2006;163(12):2090–95.
11. Gaebel W, Riesbeck M, Wӧlwer W, et al. Relapse prevention in first-episode schizophrenia –maintenance
vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry 2011;72(2):205–18.
12. Ganguli R. Rationale and strategies for switching antipsychotics. Am J Health Syst Pharm 2002;59:22–6.
13. Gautam D, Han SJ, Hamdan FF, et al. A critical role for beta cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo. Cell Metab 2006;3(6):449–61.
14. Haase HJ, Janssen PAJ. The action of neuroleptic drugs. Chicago, 1965.
15. Harvey EJ, Taylor DM, Flanagan RJ. D2 receptor occupancy under re- commended and high doses of olanzapine. J Psychopharmacol 2001;15:213–14.
16. Haslemo T, Eikeseth PH, Tanum L, et al. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol 2006;62:1049–53.
17. Haslemo T, Refsum H, Molden E. The effect of ethinylestradiol-containing contraceptives on the serum concentration of olanzapine and N-desmethyl olanzapine. Br J Clin Pharmacol 2011;71(4):611–15.
18. Hiemke C, Peled A, Jabarin M, et al. Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. J Clin Psychopharmacol 2002;22:502–06.
19. Kapur S, Zipursky RB, Remington G, et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998;155:921–28.
20. Kelly DL, Conley RR, Tamminga CA. Differential olanzapine plasma con-centrations by sex in a fixed-dose study, Schizophr Res 1999;40:101–4.
21. Kelly DL, Richardson CM, Yu Y, et al. Plasma concentrations of high-dose olanzapine in a doubleblind
erossover study. Hum Psychopharmacol 2006;21:393–98.
22. Kinon BJ, Basson BR, Gilmore JA, et al. Strategies for switching from conventional antipsychotic
drugs or risperidone to olanzapine. J Clin Psychiatry 2000;61:833–40.
23. Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic
medications for off-label uses inadults: a systematic review and meta-analysis. JAMA 2011;306(12):1359–69.
24. Markowitz JS, DeVane CL. Suspected ciprofloxacin inhibition of olanzapine resulting in increased
plasma concentration. J Clin Psychopharmacol 1999;19:289–91.
25. Masand PS. A review of pharmacologic strategies for switching to atypical antipsychotics. Prim Care Companion J Clin Psychiatry 2005;7:121–29.
26. Mauri MC, Volonteri LS, Colasanti A, et al. Clinical pharmacokinetics of atypical antipsychotics:a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 2007;46:359–88.
27. Melkersson KI, Dahl ML. Relationship between levels of insulin or triglycerides and serum concentrations
of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology (Berl) 2003;170:157–66.
28. McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, doubleblind 52-week comparison. Am J Psychiatry. 2007;164(7):1050–60.
29. Nord M, Nyberg S, Brogren J, et al. Comparison of D2 dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extendedrelease formulations in healthy subjects. Intern J Neuropsychopharmacol (2011);14: 1357–66.
30. Oransky I. Paul Janssen. Lancet 2004;363:251.
31. Theisen FM, Haberhausen M, Schulz E, et al. Serum levels of olanzapine and its N-desmethyl
and 2-hydroxymethyl metabolites in child and adolescent psychiatric disorders: effects of dose, diagnosis, age, sex, smoking, and comedication. Ther Drug Monit 2006;28:750–59.
32. Wu TH, Chiu CC, Shen WW, et al. Pharmacokinetics of olanzapine in Chinese male schizophrenic patients with various smoking behaviors. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1889–83.


Об авторах / Для корреспонденции


Ястребов Денис Васильевич – отделение новых средств и методов терапии психических и поведенческих расстройств ФГУ “Государственный научный центр социальной и судебной психиатрии им. В.П. Сербского” Минздравсоцразвития России. e-mail: dvyastrebov@gmail.com


Похожие статьи


Бионика Медиа